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The total reimbursement for anti-diabetic drugs in U.S. Medic-
aid programs increased from $90.7 million in 1991 to $1.1
billion in 2005. The number of prescriptions increased dramat-
ically from 4.1 million in 1991 to 18.2 million in 2005. The cost
per prescription for brand-name drugs increased over time as
well. The relatively expensive drugs in 2005 were Actos ($169),
Avandia ($133), Avandamet ($150), Prandin($113), and Starlix
($103). The total number of prescriptions for the ﬁrst-generation
sulfonylureas dropped from 1.1 million in 1991 to 292,000 in
2005, while the number of prescriptions for other classes
increased over the years. For example, the number of prescrip-
tions for biguanides increased from 39,849 in 1995 to 5.7
million in 2005, the number of thiazolidinedione prescriptions
increased from 323,581 in 1997 to 4.5 million in 2005, and the
number of meglitinide prescriptions increased from 30,790 in
1998 to 425,516 in 2005. CONCLUSION: Increased expendi-
ture for oral anti-diabetic drugs was caused by both increased
price and utilization. When the generic drugs metformin, glip-
izide, and glyburide were introduced to the market, the use of
their brand-name counterparts decreased dramatically due to
Medicaid’s policies encouraging generic substitution.
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INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON
DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE
2 DIABETES
Durden ED, Bizier R, Huse D
Thomson Medstat, Cambridge, MA, USA
OBJECTIVES: The American Diabetes Association recommends
treating diabetes patients to a target hemoglobin A1c level of 7%
or less. Our objective was to examine the inﬂuence of A1c test
results on decisions to initiate exogenous insulin supplementa-
tion in Type 2 diabetes. METHODS: A database of clinical lab-
oratory results linked to health plan claims (MarketScan Lab)
was used to identify patients with a diagnosis of Type 2 diabetes.
Their ﬁrst A1c test result between July 2003 and June 2005 was
identiﬁed and patients were classiﬁed as at target (less than 7),
above target (7–9), or poorly controlled (>9). The study sample
was restricted to patients who had 6 months of claims history
prior to and 6 months after the index test, and who received only
oral antidiabetes therapy during the pre-test period. Addition of
insulin to the regimen within 6 months after the test was
assessed. RESULTS: A total of 4836 patients were identiﬁed,
including 2450 (51%) who were at target, 1567 (32%) above
target, and 819 (17%) poorly controlled. Insulin was added to
the regimen of 12.9% of patients with poor control, 4.3% of
those above target, and 1.5% of those at target (p < 0.00001).
Among poorly controlled patients insulin was added in 22.0%
of patients already on 3 oral medications, 12.6% of those with
2 oral medications, and 8.6% of those with 1 oral medication
(p < 0.001). A1c test result and prior oral medication use
remained signiﬁcant predictors of insulin supplementation after
controlling for demographic variation. CONCLUSION: High
levels of A1c indicating poor glycemic control led some patients
with Type 2 diabetes to initiate insulin supplementation, par-
ticularly those already receiving multiple oral medications.
However, poorly controlled patients were still most likely to
remain on oral therapy only, even if they were already using 3
or more medications.
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IMPACT OF PATIENT EDUCATION ON HBA1C REDUCTION
IN DIABETIC PATIENTS WITH CONCOMITANT
HYPERTENSION
Shaya FT1, Samant ND1, Saunders E2
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
2University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: The purpose of this study was to assess the
impact of patient and physician education on Hemoglobin A1c
(HbA1c) control in diabetes patients with concomitant hyper-
tension. METHODS: The analysis was based on a subset of
those enrolled in the Baltimore Partnership Programs to Reduce
CVD Disparities project, with one year of follow-up. Patients
and their physicians were randomly assigned to either interven-
tion or control group, in a 2X2 nested case control factorial
design. Patients and physicians participated in educational ses-
sions. We calculated the change in HbA1c value, from baseline,
to one year follow-up. Multiple regression was used to assess the
effects of interventions on HbA1c change adjusting for age, race,
gender and hypertension. RESULTS: Out of the study cohort of
114 patients, most were African American (96%) and female
(62%). Mean baseline HbA1c values were higher among males
vs. females (8.7% vs. 8.6%), African Americans vs. Caucasians
(8.7% vs. 8.15%), Intervention patients vs. control patients
(9.15% vs. 8.28%), and patients of Intervention vs. control
physicians (8.94% vs.8.33%). The drop in the HbA1c values
was greater among intervention patients (−0.6 vs. 0.2) and
patients of intervention physicians (−0.32 vs. 0.01). After con-
trolling for age, race, gender and hypertension, the drop in
HbA1c in the patient intervention group was greater than the
control and the drop in HbA1c in the patients of intervention
physicians was greater than the control though statistically non-
signiﬁcant. CONCLUSION: In this patient sample, greater drop
in HbA1c is seen among the intervention patients and patients
of Intervention physicians. These results highlight the inﬂuence




PRELIMINARY VALIDATION OF THE COGNITIVE DISTRESS,
FATIGUE, HYPERGLYCEMIA AND HYPOGLYCEMIA
SUBSCALES OF THE DIABETES SYMPTOM CHECKLIST
REVISED (DCSR) FOR USE IN CLINICAL TRIALS INVOLVING
PATIENTS WITH TYPE 1 OR TYPE 2 DIABETES
Kelly AA1, Hayes RP2
1Florida A&M University,Tallahassee, FL, USA, 2Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVES: The Diabetes Symptom Checklist-Revised
(DSCR) is a 34-item, 7-subscale instrument designed to provide
a comprehensive measure of diabetes-associated symptoms.
When evaluating antihyperglycemic medications in a clinical trial
however, only those symptoms affected by ﬂuctuations in
glycemic control (e.g., hyperglycemia) would be expected to
change. Therefore, the objective of this study was to validate the
DSC-R Cognitive Distress, Fatigue, Hyperglycemia, and Hypo-
glycemia subscales as individual measures of symptom groups to
be targeted in clinical trials of antihyperglycemic medications.
METHODS: In two clinical trials evaluating antihyperglycemic
medications (Study 1: insulin therapy in 137 patients with type
1 diabetes; Study 2: oral therapy in 150 patients with type 2 dia-
betes), participants were administered the DSC-R at several time
periods including screening, baseline and endpoint. To conﬁrm
the factorial validity of the subscales, a promax factor analysis
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was performed. Cronbach’s alpha coefﬁcients and Pearson’s
product moment correlations were calculated to estimate relia-
bility. To establish construct validity, correlation coefﬁcients
were calculated between the subscales and vitality, well-being,
treatment satisfaction, and/or baseline glycosylated hemoglobin
(HbA1c). Standard errors of measurement (SEMs) were calcu-
lated to estimate minimal important difference. RESULTS: In
both studies: 1) factor analysis conﬁrmed the factor structure of
the four subscales with the exception that the “sleepiness or
drowsiness” item loaded with the Fatigue subscale items rather
than the Cognitive Distress items; 2) test-retest reliability (all
>0.68) and Cronbach’s alpha coefﬁcients (all >0.79) were accept-
able; 3) associations between subscales and other patient-
reported outcomes measures and/or HbA1c were signiﬁcant (p <
0.05) and in the hypothesized directions; and 4) SEMs were
approximately 0.5 on a 1 to 5 scale. CONCLUSION: Prelimi-
nary validation indicates that the Cognitive Distress, Fatigue,
Hyperglycemia, and Hypoglycemia subscales are potentially reli-
able and valid individual measures for use in clinical trials eval-
uating antihyperglycemic medications in patients with type 1 or
type 2 diabetes.
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HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES
MELLITUS: RELATIONSHIPS IN A CROSS-SECTIONAL STUDY
Sundaram M, Miller LA, Kavookjian J
West Virginia University School of Pharmacy, Morgantown, WV, USA
OBJECTIVES: This study reports relationships between two
instruments of health status and an instrument of quality of life
(QoL) in a cross-sectional study among patients with Type 2 Dia-
betes Mellitus (T2DM). METHODS: Of generic health status
(SF-12 and EuroQoL EQ-5D), and diabetes-speciﬁc QoL (Audit
of Diabetes Dependent Quality of Life–ADDQoL). Patient
reported data were merged with retrospective clinical data
including A1C, comorbidities, diabetes complications score,
BMI, and others, from electronic medical records. RESULTS:
Usable response rate was 44.3% (n = 385). Mean A1C of respon-
dents was 7.2 (+1.4), mean diabetes duration was 10.2 (+9.1)
years, and 62.1% were obese (BMI >30). About 49% of respon-
dents were on oral medications only, 31.7% on oral medications
and insulin, and 9.4% on insulin only. Spearman correlations of
the EQ-5D were 0.640 with the SF PCS-12, 0.534 with the SF
MCS-12, and 0.316 with the ADDQoL (all p < 0.001). Insulin
use and diabetes-related complications were signiﬁcantly associ-
ated with poorer scores on all measures. Only ADDQoL scores
were signiﬁcantly better among those with the ADA recom-
mended A1C level <7.0 (p = 0.002). Nearly 73% respondents
reporting moderate problems with mobility and usual activities
on the EQ-5D were clinically obese. Obesity signiﬁcantly
impaired SF-12 scores but not ADDQoL scores. A path analytic
model relating SF-12 scores with EQ-5D and ADDQoL scores
had good ﬁt (Chi sq. = 1.32, p = 0.250; TLI = 0.99; RMSEA =
0.03). CONCLUSION: All three measures discriminated on the
basis of diabetes treatment group and number of complications.
Health status was impaired by obesity in T2DM. Those patients
with poorer glycemic control had lower scores on the disease-
speciﬁc QoL instrument. The health status and QoL instruments
used in the study appeared to measure different constructs, con-




CAN PATIENTS ACCURATELY RATE THEIR ADHERENCE TO
MEDICATIONS?
Nau DP1, Steinke D1, Elston Lafata J2,Williams LK2, Divine G2,
Austin R2, Pladevall M2
1University of Kentucky, Lexington, KY, USA, 2Henry Ford Health
System, Detroit, MI, USA
OBJECTIVES: To compare self-report measures of medica-
tion adherence with claims-based measures of adherence.
METHODS: A mail survey was conducted of persons with dia-
betes in the Henry Ford Health System in 2006. Prescription
claims were obtained for survey respondents, and the analyses
were conducted with 932 persons who were using at least two
oral medications for diabetes. The self-reported measures of
adherence included a six-category self-rating of adherence which
ranged from “never” to “all of the time” and a visual analog
scale (VAS) wherein patients marked the percentage of time that
they followed the medication regimen as directed The claims-
based measure was the continuous measure of availability
(CMA) reported as a scale from 0 to 100%. Two dichotomous
measures of adherence were created: CMA-80 (CMA cut at
80%); VAS-80 (VAS cut at 80%). RESULTS: The VAS and CMA
demonstrated a linear relationship in the expected direction with
the self-selected categories for medication adherence. The mean
VAS scores ranged from 62.4% to 98.1% across the categories
(F = 180.4, p < 0.001), and the CMA ranged from 66.1% to
85.4% (F = 15.8, p < 0.001). The VAS had a moderate correla-
tion with the CMA (r = 0.25). The mean (±SD) for the VAS and
CMA were 95.5 (±10.4) and 83.2 (±15.9), respectively. For dif-
ference scores (VAS minus CMA), 33.5% of respondents had a
VAS that was at least 1 SD higher than CMA. When comparing
the VAS-80 to the CMA-80, the area under the ROC curve was
0.54 (2.3% were categorized as adherent by CMA-80, but non-
adherent by VAS-80; 30.2% were categorized as non-adherent
by CMA-80, but adherent by VAS-80). CONCLUSION: Self-
reported adherence to medications by patients with diabetes is
moderately correlated with claims-based estimates. However,
about one-third of respondents will have a VAS that is signiﬁ-
cantly higher than CMA.
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MEDICATION ADHERENCE IN PATIENTS WITH DIABETES
DURING THE MEDICARE PART D BENEFIT COVERAGE GAP
PERIOD
Prasla K1, Godley P1, Rascati KL2, Gabrillo E1
1Scott and White Health Plan,Temple,TX, USA, 2The University of
Texas at Austin, Austin,TX, USA
OBJECTIVES: To evaluate medication adherence of select lipid
lowering and oral anti-diabetic medications in diabetic patients
during the Medicare Part D beneﬁt coverage gap. METHODS:
This was a retrospective evaluation of pharmacy claims data-
base. The evaluation consisted of standard Medicare Part D
beneﬁt patients at an 185,000 member managed care organiza-
tion during January 1, 2006 through November 30, 2006. Study
patients included anyone who encountered claims for both a 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin) and an oral (PO) anti-diabetic medication during January
2006, and reached the coverage gap by November 30, 2006.
Patients were excluded if they subsequently experienced cata-
strophic coverage or did not reach the coverage gap during 2006.
Medication adherence was measured using pharmacy claims
data to calculate medication possession ratios (MPR). A descrip-
tive comparison of MPR during “pre-coverage gap days” and
